You are here

  • Home
  • Archive
  • Volume 10, Issue Suppl 2
  • 1389 GIGA-564 a third generation anti CTLA 4 with minimal ability to block CTLA 4 binding to B7 ligands has enhanced efficacy but reduced toxicity compared to ipilimumab in preclinical models

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Novel Single-Agent Immunotherapies
1389 GIGA-564 a third generation anti CTLA 4 with minimal ability to block CTLA 4 binding to B7 ligands has enhanced efficacy but reduced toxicity compared to ipilimumab in preclinical models
Free

 

Online download statistics by month:

Online download statistics by month: November 2022 to September 2024

AbstractFullPdf
Nov 2022338029
Dec 202262023
Jan 202328012
Feb 202350019
Mar 202364017
Apr 20234806
May 20233404
Jun 20231602
Jul 202328010
Aug 202354015
Sep 20237409
Oct 20236809
Nov 20238209
Dec 202372014
Jan 20242000
Feb 20246803
Mar 20243002
Apr 20246009
May 20245204
Jun 20244805
Jul 20244607
Aug 202474010
Sep 20248008
Total14960226